US EditionDual Adjuvants in HIV Vaccine Elicits Broader B Cell Response
Summary by Inside Precision Medicine
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Dual Adjuvants in HIV Vaccine Elicits Broader B Cell Response
Researchers from MIT and the Scripps Research Institute have shown that combining two adjuvants with a protein-based HIV vaccine candidate can elicit a significantly stronger immune response compared to traditional vaccine formulations. The mouse study, published in Science Translational Medicine, suggests that dual-adjuvant strategies could be an avenue to develop single-dose vaccines for viruses such as HIV, SARS-CoV-2, and influenza. “This ap…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
